Next Article in Journal
Chemical Composition, Antioxidant, Antibacterial, and Hemolytic Properties of Ylang-Ylang (Cananga odorata) Essential Oil: Potential Therapeutic Applications in Dermatology
Previous Article in Journal
Correction: Viveros-Paredes et al. Neuroprotective Effects of β-Caryophyllene against Dopaminergic Neuron Injury in a Murine Model of Parkinson’s Disease Induced by MPTP. Pharmaceuticals 2017, 10, 60
Previous Article in Special Issue
Click Chemistry in Polymersome Technology
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 17
Issue 10
10.3390/ph17101375
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Exploring Benzo[h]chromene Derivatives as Agents against Protozoal and Mycobacterial Infections

by
Mariano Walter Pertino
1,*,
Alexander F. de la Torre
2,
Guillermo Schmeda-Hirschmann
1,
Celeste Vega Gómez
3,
Miriam Rolón
3,
Cathia Coronel
3,
Antonieta Rojas de Arias
3,
Carmen A. Molina-Torres
4,
Lucio Vera-Cabrera
4 and
Ezequiel Viveros-Valdez
5
1
Instituto de Química de Recursos Naturales, Universidad de Talca, Campus Lircay, Talca 3480094, Chile
2
Department of Medical Physics, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53705, USA
3
Centro para el Desarrollo de la Investigación Científica (CEDIC), Manduvirá 635, Asunción CP 1255, Paraguay
4
Servicios de Dermatología, Hospital Universitario “José E. González”, Universidad Autónoma de Nuevo León, Monterrey 64460, NL, Mexico
5
Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza 66455, NL, Mexico
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2024, 17(10), 1375; https://doi.org/10.3390/ph17101375
Submission received: 1 October 2024 / Revised: 9 October 2024 / Accepted: 11 October 2024 / Published: 16 October 2024
(This article belongs to the Special Issue Click Reactions in Medicinal Chemistry II)
Browse Figures
Versions Notes

Abstract

:
Background/Objectives: In this study, the efficacy of benzo[h]chromene derivatives as antiprotozoal and antimycobacterial agents was explored. Methods: A total of twenty compounds, including benzo[h]chromene alkyl diesters and benzo[h]chromene-triazole derivatives, were synthesized and tested against Trypanosoma cruzi, Leishmania braziliensis, L. infantum, and strains of Mycobacterium abscessus and Mycobacterium intracellulare LIID-01. Notably, compounds 1a, 1b, 2a, and 3f exhibited superior activity against Trypanosoma cruzi, with IC50 values of 19.2, 37.3, 68.7, and 24.7 µM, respectively, outperforming the reference drug benznidazole (IC50: 54.7 µM). Results: Compounds 1b and 3f showed excellent selectivity indices against Leishmania braziliensis, with SI values of 19 and 18, respectively, suggesting they could be potential alternatives to the commonly used, but more selective, miltefosine (IC50: 64.0 µM, SI: 43.0). Additionally, compounds 1a, 1b, and 3f were most effective against Leishmania infantum, with IC50 values of 24.9, 30.5, and 46.6 µM, respectively. Compounds 3f and 3h were particularly potent against various Mycobacterium abscessus strains, highlighting their significance given the inherent resistance of these bacteria to standard antimicrobials. Conclusions: The sensitivity of Mycobacterium intracellulare LIID-01 to these compounds also underscored their potential in managing infections by the Mycobacterium avium–intracellulare complex.

Graphical Abstract

1. Introduction

Two significant parasitic diseases in developing countries are Leishmaniasis and Chagas disease (CD), caused by protozoa of the order Kinetoplastidae, Leishmania spp. and Trypanosoma cruzi, respectively. These are in the most important category of neglected tropical diseases. Chaga’s disease has a four-stage life cycle which has three clinical stages: acute (often asymptomatic, 4–8 weeks), indeterminate (10–20 years), and chronic. In the chronic state when the parasites infiltrate the inner organs (myocardium and intestine), the recurrent process of the disease will continue for years, causing permanent harm [1]. Chagas disease is present in 21 countries in Latin America [2,3,4,5] and in at least ten non-endemic countries, including the United States, Spain, Italy, Japan, and Australia, considering the globalization by immigration [6]. Leishmaniasis is a disease caused by at least 20 species of Leishmania. In humans, the parasite causes both systemic and cutaneous disease, along with many indirect effects [1]. Leishmaniasis is endemic in 98 countries and territories in the world, affecting millions of people. In our research, we have specifically focused on in vitro evaluation of the synthesized compounds on L. braziliensis and L. infantum. In tropical and subtropical Latin America, L. braziliensis is widespread and causes both cutaneous and mucocutaneous diseases. Leishmania infantum is a major human disease, with dogs as the confirmed primary infection reservoir. It can contribute to visceral leishmaniasis and lead to death without treatment by infecting vital organs such as the spleen and liver [7]. The extracellular dividing forms of the parasite inside the insect vectors are promastigotes in Leishmania spp. and epimastigotes in T. cruzi. These models are suitable for preliminary in vitro screening because they are simple to cultivate under laboratory conditions [8,9].
Currently, the only choice for controlling these parasites is chemotherapy. Nevertheless, despite advancements in chemotherapy, there is an urgent and compelling need for the development of new drugs [10]. The drugs available to treat CD until recently were limited to the nitroaromatic heterocycles, nifurtimox, and benznidazole. These compounds are effective in treating only the acute phase of the disease but, in chronically infected adults, showed low efficacy. Moreover, they are associated with numerous side effects such as hypersensitivity, bone marrow depression, peripheral polyneuropathy, and digestive manifestations, among others [11,12]. Similarly, drugs currently used for leishmaniasis therapy have modest effectiveness, require extended treatment, have a high cost, and are accompanied by adverse effects. Furthermore, the parasites have been shown to develop resistance to these drugs [13]. Therefore, the discovery of new drugs is a priority. Only 3.8% of drugs approved by the FDA between 2000 and 2011 were for neglected diseases such as leishmaniasis, CD, and sleeping sickness, which together represent more than 10% of the global burden of diseases [14].
Tuberculosis (TB) is a significant global health concern, primarily caused by Mycobacterium tuberculosis (Mtb) and responsible for a substantial number of deaths each year [15]. Although antimycobacterial drugs are available for treatment, only a handful of new chemical entities have progressed to clinical trials [16]. In 2018, the World Health Organization reported around 484,000 new cases of resistance to rifampicin, of which 78% had multidrug-resistant TB (MDR-TB) [17]. In addition to Mtb, there are over 170 different species of mycobacterial nontuberculous (NTM) that cause a broad pathological spectrum such as TB-like pulmonary, extra-pulmonary, and disseminated diseases. Often, NTM does not respond to TB treatments and usually requires long and complex drug therapies, and most NTM are resistant to many antimicrobials [18].
Lapachol, a yellow crystalline pigment found in the bark of the South American lapacho tree (Bignoniaceae), exhibits a wide array of biological activities. The large “lapacho” tree (Hadroanthus impetiginosus (Mart. ex DC.) Mattos; syno-nyms: Tabebuia impetiginosa (Mart. ex DC) Standley and Tabebuia avellanedae Lorentz ex Griseb.) is the botanical source of the prenylated naphthoquinone lapachol. The tree is common in Argentina, Paraguay, Uruguay, and southern Brazil. Lapachol has been used to obtain many bioactive compounds with a variety of structural scaffold; this can be cyclized to form α-lapachone and β-lapachone under strong acidic conditions and to dehydro-α-lapachone and dehydro-β-lapachone with DDQ. However, the synthesis of benzo[h]chromene derivatives from lapachol is not common. Hooker had previously reported the formation of benzo[h]chromene diacetate derivatives, albeit in a mixture of α and β-lapachone in a 1.4:1 ratio [19]. Recently, we have achieved enantioselective synthesis to the β-isomer of benzo[h]chromene diester derivatives [20].
In recent years, several studies have explored the incorporation of triazole rings in quinones like lapachol, β-lapachone, and nor-β-lapachone, producing derivatives with remarkable activity against T. cruzi and Leishmania (Figure 1) [21,22,23,24,25,26]. Previously, we reported the synthesis, antiprotozoal, and antibacterial activity of new lapachol–triazole derivatives [26].
Following our work on new lead compounds for drug discovery, our present research focuses on the synthesis and evaluation of 18 novel benzo[h]chromene-triazole derivatives. The compounds were assessed against the epimastigote form of T. cruzi and promastigotes of L. braziliensis and L. infantum. Furthermore, we conducted a comprehensive assessment of the compounds’ cytotoxicity on murine fibroblasts and investigated the impact of these compounds on the growth of mycobacteria tuberculous and nontuberculous (NTM).

2. Results and Discussion

2.1. Chemistry

The synthesis of the benzo[h]chromene-triazole derivatives (designated as 2a–2i and 3a–3i) followed a stepwise procedure, outlined in Scheme 1. Initially, we generated the benzo[h]chromene diesters, 1a and 1b, through the esterification of lapachol. As previously detailed, we achieved the esterification of lapachol by employing various carboxylic acids, N,N-diisopropylcarbodiimide (DIC), and a catalytic amount of 4-dimethylaminopyridine (DMAP) [20]. The synthesis of benzo[h]chromene derivatives involves a two-stage process. First, we produced the monoester of lapachol, which was followed by a concerted pericyclic 6π intra-cyclization. According to the findings, direct esterification in a one-pot reaction is the preferred method for obtaining lapachol monoester, while a stepwise approach is the most suitable for generating benzo[h]chromene derivatives. Two alkynyl esters were prepared and then treated with different aromatic azides using click chemistry to produce 18 new benzo[h]chromene-triazole derivatives. All the products were characterized by spectroscopic means (see the Experimental Section and Supplementary Information).

2.2. Biological Evaluation

2.2.1. Antiprotozoal Activity

In this study, we synthesized a range of benzo[h]chromene- diesters (compounds 1a and 1b) and benzo[h]chromene-triazole derivatives (compounds 2a–2i and 3a–3i) and investigated their potential as antiprotozoal agents (Table 1 and Table 2). Among the 20 compounds examined, only four exhibited notable antiprotozoal activity against epimastigote forms of T. cruzi and promastigotes of L. braziliensis and L. infantum (Table 1).
Compounds 1a, 1b, 2a, and 3f showed IC50 values of 19.2, 37.3, 68.7, and 24.7 μM, respectively, against T. cruzi. These values are comparable to or better than those of the reference compound (benznidazole, IC50: 54.7 μM). Additionally, these compounds demonstrated selectivity indexes (SIs) ranging from 3 to 13, while benznidazole had an SI of 14.0.
Remarkably, the alkyl benzo[h]chromene-diester derivatives (compounds 1a and 1b) showed better activity against T. cruzi than most corresponding benzo[h]chromene-triazole derivatives. Our recent study [26] on lapachol–triazole derivatives demonstrated a similar trend, with lapachol–alkyl esters showing equivalent or superior activity to lapachol–triazole derivatives.
A comparison between alkyl derivatives 1a and 1b revealed no significant difference in trypanocidal activity, suggesting that the side chain exerts limited influence on these alkynes. These findings are consistent with the results obtained from previously reported lapachol–alkyl ester derivatives [26]. The derivatives 2f and 3f exhibited similar T. cruzi activity, with values of 21.4 and 24.7 μM, respectively. Both compounds contain a tosyl group, differing only in chain length. However, compound 2f was the most cytotoxic among the evaluated derivatives, while compound 3f showed no cytotoxicity, making it the derivative with the best selectivity index.
The in vitro inhibition of Leishmania proliferation was assessed against two promastigote strains. Compounds 1a, 1b, 2f, and 3f were the most effective derivatives against L. braziliensis, with IC50 values of 10.7, 6.7, 14.5, and 17.6 μM, respectively. Compounds 1b (SI: 19) and 3f (SI: 18) exhibited the most favorable selectivity indexes. While the reference compound miltefosine displayed greater selectivity, its IC50 value was higher than that of the derivatives (IC50: 64.0 μM).
The most effective compounds against L. infantum were the alkynes 1a and 1b, with IC50 values of 24.9 and 30.5 µM, respectively. Meanwhile, the best selectivity index was for derivative 3f, with an SI value of 7, compared with the standard drug miltefosine (SI: 109.7). There is a variation in the activity against L. infantum. However, alternative medications are required because miltefosine resistance has been reported in recent papers [27,28].

2.2.2. Antibacterial Activity

The emergence of antibiotic resistance has become a significant global challenge in the context of infectious diseases, particularly those caused by mycobacteria. The pressing need for innovative treatment options has driven extensive research into the evaluation of a diverse array of compounds for their potential efficacy against mycobacterial infections [29]. Among these, natural products and their semi-synthetic derivatives have played a pivotal role, exemplified by the utilization of rifampicin, streptomycin, amikacin, capreomycins, and cycloserine as essential antitubercular agents [30]. Furthermore, the naphthoquinone lapachol has demonstrated potential activity against tuberculosis strains [31,32].
Ester prodrugs offer a classical strategy for masking polar alcohol and carboxylic acid functionalities and improving cell permeability [33]. This property is of paramount importance in the search for novel antituberculosis agents, as mycobacterial cell walls are characterized by complex structures that are highly hydrophobic and resistant to the permeation of many compounds [34]. In this study, we observed that the benzo[h]chromene derivates, can be considered interesting compounds for the discovery of novel antimycobacterial molecules to treat NTM infections. Notably, we have identified derivatives 3f and 3h as exhibiting substantial activity against all analyzed M. abscessus strains, which is remarkable considering the inherent resistance of M. abscessus to most conventionally used antimicrobials. The primary screens for M. abscessus often yield hit rates lower than 0.1% [35].
On the other hand, the most susceptible strain was found to be M. intracellulare LIID-01. This finding carries significant clinical relevance, as the Mycobacterium avium–intracellular complex is a primary cause of NTM infections in individuals with HIV/AIDS [36]. The limited availability of active drugs has resulted in prolonged and challenging treatment regimens [37]. This underscores the importance of our investigation into benzo[h]chromene as potential therapeutic agents for addressing antibiotic resistance in the context of NTM infections. In a related context, we observed that compound 3f exhibited notable antimicrobial activity against both Gram-positive and Gram-negative bacteria, as detailed in Table 3. This finding is particularly significant due to the escalating concern surrounding antibiotic resistance within the latter group of microorganisms [38]. Notably, this resistance extends to pathogens such as mycobacteria, where the membrane is recognized as a pivotal factor contributing to this resistance [39]. The research conducted by Sangwan et al. in 2023 [40] has recently provided compelling evidence for the potential of compounds incorporating 1,2,3-triazole hybrids with amine-ester functionality.

2.3. ADME In Silico Approach

We also studied the ADME properties of the compounds predicted using SwissADME server (Table 4). The Lipinski’s Rule, also known as the “Rule of Five”, is a fundamental concept in drug discovery and development. It was introduced by Lipinski et al. [41] to delineate the physicochemical parameters associated with oral drug absorption and the likelihood of becoming successful oral drugs. According to this rule, compounds are more likely to be orally active if they have certain physicochemical properties, such as a molecular weight below 500, a Log P (octanol–water partition coefficient) less than 5, no more than 5 hydrogen bond donors, and no more than 10 hydrogen bond acceptors. Only compounds 1a and 1b comply with these rules, with no violations observed for compound 1a and one violation for compound 1b. The remaining compounds do not adhere to these criteria, with two violations identified for compounds 2e, 3e, 2h, and 3h, and three violations for the remaining compounds. While Lipinski’s Rule serves as a guideline for drug design, there are exceptions where molecules outside these parameters are still used as drugs, highlighting the complexity of drug development and the importance of considering multiple factors in drug design and optimization [42].
The topological polar surface area (TPSA) is another feature of interest, as drugs with a low TPSA (≤140 Å2) typically have higher oral bioavailability [43]. Among the twenty synthesized compounds, twelve demonstrate favorable TPSA values (refer to Table 4). Predictions suggest limited gastrointestinal absorption for the compounds, except for compounds 1a and 1b, which may be attributed to their low calculated aqueous solubility (LogS). Additionally, only compound 1a exhibits the capability to traverse the blood–brain barrier (BBB). Considering both experimental bioactivity and in silico data, compound 1a emerges with a favorable drug-likeness profile and excellent chemical stability, positioning it as the leading candidate.
Table 4. Physicochemical and pharmacokinetic descriptors calculated with SwissADME.
Table 4. Physicochemical and pharmacokinetic descriptors calculated with SwissADME.
Physicochemical PropertiesLipophilicityWater SolubilityPharmacokinetics
MW 1RB 2HBA 3HBD 4TPSA 5Log Po/w 6(mol/L) GI abs 7BBB 8log Kp 9
1a402.4485061.834.739.14 × 10−4HighYes−5.47
1b430.49105061.835.231.79 × 10−4HighNo−5.14
2a640.691290123.255.391.35 × 10−6LowNo−5.74
3a668.741490123.256.162.52 × 10−7LowNo−5.40
2b700.7414110141.715.516.97 × 10−7LowNo−6.14
3b728.7916110141.715.871.30 × 10−7LowNo−5.80
2c709.581290123.256.487.35 × 10−8LowNo−5.26
3c737.631490123.257.101.40 × 10−8LowNo−4.93
2d668.741290123.285.972.49 × 10−7LowNo−5.39
3d696.791490123.256.644.70 × 10−8LowNo−5.06
2e1004.9424230299.512.929.60 × 10−6LowNo−10.94
3e1033.0026230299.513.181.77 × 10−6LowNo−10.60
2f796.8714130208.295.663.75 × 10−8LowNo−6.87
3f840.9616130208.295.501.53 × 10−9LowNo−6.08
2g709.581290123.256.607.35 × 10−8LowNo−5.26
3g737.631490123.257.191.40 × 10−8LowNo−4.93
2h758.7416130214.894.495.84 × 10−8LowNo−6.79
3h786.7918130214.895.031.08 × 10−8LowNo−6.45
2i826.531490123.256.678.57 × 10−8LowNo−5.97
3i854.591690123.257.471.62 ×10−8LowNo−5.64
1 Molecular weight (g/mol); 2 number of rotatable bonds; 3 number of hydrogen bond acceptors; 4 number of hydrogen bond donors; 5 topological polar surface area [44]; 6 average of iLOGP, XLOGP, WLOGP, MLOGP, and SILICOS-IT predictions (consensus Log Po/w) [45]; 7 gastrointestinal absorption; 8 blood–brain barrier permeation; 9 skin permeation: QSPR model (cm/s) [46].

3. Materials and Methods

3.1. Chemistry

3.1.1. General Overview

1H NMR and 13C NMR spectra were recorded at 400 MHz for 1H and 100 MHz for 13C, respectively using a Bruker Avance 400 instrument (Bruker Corporation, Rheinstetten, Baden-Württemberg, Germany). Chemical shifts (δ) are reported in parts per million relative to the residual solvent signals, and coupling constants (J) are reported in Hertz. High-resolution ESI mass spectra were obtained from a Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer, an RF-only hexapole ion guide, and an external electrospray ion source (Bruker Daltonics Inc., Billerica, MA, USA). Flash column chromatography was carried out using silica gel 60 (230–400 mesh) from Merck KGaA, Darmstadt, Hesse, Germany. Analytical thin layer chromatography (TLC) was performed using silica gel on aluminum sheets (Merck KGaA, Darmstadt, Hesse, Germany).

3.1.2. General Procedure Followed for Esterification

A solution of the acid (2.0 equiv.) in a mixture of DCM (0.5 mL) with DIC (2.0 equiv.) was stirred for 10 min at room temperature. Then, lapachol with a catalytic amount of DMAP dissolved in DCM (0.5 mL) were added together, and the reaction was stirred for 12 h at room temperature. Next, 1 mL of THF followed by the correspondent azide (2.2 equiv.) was added, and the reaction mixture was treated with solutions of CuSO4·5H2O (20 mol%) and sodium ascorbate (40 mol%), enabling the formation of Cu(I) in situ. After the reaction completion (monitored by TLC), the reaction mixture was diluted with 20 mL of DCM and washed successively with NaHCO3 (sat.), brine, and water. The extract was dried over Na2SO4 and purified by silica gel column chromatography.

3.2. Biology

3.2.1. Antiprotozoal Assays

For in vitro studies of T. cruzi. the clone CL-B5 was used. Parasites were stably transfected with the Escherichia coli β-galactosidase gene (lacZ), provided by Facultad de Farmacia (Universidad Complutense de Madrid). Epimastigotes were grown at 28 °C in liver infusion tryptose broth (Difco, Detroit, MI, USA) with 10% fetal bovine serum (FBS) (Gibco, Carlsbad, CA, USA), penicillin (Ern S.A., Barcelona, Spain), and streptomycin (Reig Jofré S.A., Barcelona. Spain), as described previously [8], and harvested during the exponential growth phase. Briefly, the screening assay was performed in 96-well microplates (Sarstedt, Inc., Newton, NC, USA) with cultures that had not reached the stationary phase. Briefly, epimastigotes were seeded at 2 × 105 parasites/mL in 200 µL growth media. The plates were then incubated with the respective compounds at 28 °C for 72 h. Afterwards, 50 µL of CPRG solution was added, resulting in a final concentration of 200 µM. The plates were incubated at 37 °C for an additional 4 h and then read at 595 nm. Each concentration was tested in triplicate [9]. The efficacy of each compound was estimated by calculating the IC50 values. These values were calculated from the sigmoidal dose–response curve adjustment using the statistical software program Graph-Pad Prims 3.0. Benznidazole was used as a reference drug.
The culture of L. braziliensis (MHOM/CO/88/UA301) and L. infantum (MCAN/ES/92/BCN83) was obtained from the Facultad de Farmacia, Universidad Complutense de Madrid, Spain.
The maintenance of the strains, the form of cultivation, and the isolation of shape promastigota followed the procedures described by Roldós et al. [8]. The promastigotes were grown at 22 °C in Schneider’s Drosophila medium supplemented with 20% FBS. The assay was performed using a modification of a previous method [47]. Promastigotes (2 × 106 parasites/well) were cultured in 96-well plastic plates. Compounds were dissolved in dimethylsulfoxide (DMSO). Different dilutions of the compounds up to a 200 µL final volume were added. After 48 h at 26 °C, 20 µL of 2 mM resazurin solution was added and the oxidation–reduction was quantified at 570 and 600 nm. The solution of resazurin was prepared at 2.5 mM in phosphate-buffered solution (PBS), pH 7.4, and filtered through 0.22 µM prior to use. All tests were carried out in triplicate. Resazurin sodium salt was obtained from Sigma–Aldrich (St. Louis, MO, USA) and stored at 4 °C protected from light. The efficacy of each compound was estimated by calculating the IC50 values.

3.2.2. Cytotoxicity

The cell line used was L929, which was grown in Minimal Essential Medium (SIGMA) supplemented with 10% heat-inactivated FBS, penicillin G (100 U/mL), and streptomycin (100 µg/mL). The cell cultures were maintained at 37 °C in a humidified 5% CO2 atmosphere. The procedure for cell viability measurement was evaluated with resazurin by a colorimetric method. The cells were plated in 96-microtitre plates at 3 × 104 cells per well in 100 µL growth medium. The cells were grown overnight at 37 °C with 5% CO2. Thereafter, the medium was removed and the compounds were added in 200 µL medium for 24 h. After incubation, 20 µL of 2 mM resazurin solution was added to each well. The plates were incubated for 3 h to allow optimal oxidation–reduction. The reduction of resazurin was determined by dual wavelength absorbance measurement at 490 and 595 nm. The background was subtracted. Each concentration was assayed three times. Medium and drug controls were used in each test as blanks [48].

3.2.3. Bacterial Strains and Culture Conditions

Six clinical isolates belonging to NTM, including three strains of M. abscessus, two of M. intracellulare, and one of M. fortuitum, as well as two strains of M. tuberculosis were obtained from the Laboratorio Interdisciplinario y de Investigación Dermatológica (LIID) belonging to the Hospital Universitario José E. González (Monterrey, Nuevo León, México). The reference isolate M. tuberculosis H37Rv ATCC 27294 was obtained from the American Type Culture Collection (ATCC). The strains were activated from the frozen stocks in Lowenstein–Jensen medium and blood agar and incubated at 37 °C for 7–14 days. Gram-negative—Escherichia coli, Pseudomonas aeruginosa, and Salmonella typhi—and Gram-positive—Staphylococcus aureus, Listeria innocua, Listeria monocytogenes, Enterococcus faecalis, Bacillus cereus, and Micrococcus luteus—bacteria were subcultured on Brain Heart Infusion Broth agar and incubated at 35 °C for 24 h prior to the assays. All the strains were identified to the species level by a biochemical test or by PCR [49].

3.2.4. Determination of the Minimum Inhibitory Concentration (MIC)

MIC, defined as the minimal concentration of a compound which prevents visible growth of the bacteria, was determined by measurement of turbidity in the wells using the broth microdilution method (CLSI, 2011). Subject to NTM strains, cation-adjusted Mueller–Hinton broth (CA-MHB) was used for bacteria and rapidly growing mycobacteria (M. abscessus and M. fortuitum) and Middlebrook 7H9 broth supplemented with oleic albumin dextrose catalase (OADC) for slow growing mycobacteria (M. intracellulare). The MIC was determined after 24 h at 37 °C for Gram-positive and -negative bacteria, 72 h at 37 °C for M. abscessus and M. fortuitum strains, and after 7 to 10 days for M. intracellulare strains. The compounds were evaluated from 3.12 to 200 μg/mL. The experiments were performed in duplicates.

3.3. ADME In Silico Approach

The SwissADME server (http://www.swissadme.ch/) was used to analyze the compounds’ physicochemical characteristics, ADME (absorption, distribution, metabolism, and excretion), pharmacokinetic characteristics, drug-like nature, and biocompatibility [45]. In summary, each compound was projected to have 42 descriptors, which included physicochemical characteristics, lipophilicity, water solubility, and pharmacokinetics. The acceptability of the compounds based on bioavailability score (drug-likeness) may be evaluated using the descriptors that were derived [45].

4. Conclusions

In conclusion, our research provides valuable insights into the potential of benzo[h]chromene derivatives as antiprotozoal and antimycobacterial agents. Among the synthesized compounds, four showed promising antiprotozoal activity against T. cruzi and Leishmania strains, with compounds 1a, 1b, 2a, and 3f exhibiting particularly noteworthy results, surpassing the reference compound benznidazole in some cases. The alkyl benzo[h]chromene-ester derivatives (1a and 1b) demonstrated equal efficacy, suggesting that the side chain’s length had minimal influence on their activity, a finding consistent with previous research.
Additionally, these compounds exhibited potential against Leishmania strains, with 1b and 3f demonstrating the best selectivity indices. Although miltefosine displayed higher selectivity, it had a higher IC50 value, making the newly synthesized derivatives promising alternatives, especially considering reported miltefosine resistance.
Furthermore, the study explored the potential of benzo[h]chromene derivatives in combating mycobacterial nontuberculous (NTM) infections, a significant challenge in the field of antimicrobial therapy. Compounds 3f and 3h demonstrated effectiveness against various M. abscessus strains, highlighting their potential as antimycobacterial agents. Notably, M. intracellulare LIID-01, which is a critical concern for HIV/AIDS patients, exhibited sensitivity to these compounds. Given the limited options for treating NTM infections, the findings suggest that benzo[h]chromene derivatives may hold promise for developing novel antimycobacterial molecules.
In summary, this research opens new avenues for the development of compounds with therapeutic potential against protozoal and mycobacterial infections. These findings emphasize the importance of exploring novel chemical entities as potential treatments for challenging infectious diseases.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/ph17101375/s1. Figures S1–S40: 1H and 13C spectra of the synthesized compounds.

Author Contributions

Conceptualization, M.W.P.; methodology, A.F.d.l.T., A.R.d.A. and E.V.-V.; validation, C.V.G. and E.V.-V.; investigation, A.F.d.l.T., M.R., C.C., C.A.M.-T. and L.V.-C.; resources, G.S.-H. and L.V.-C.; writing—original draft preparation, M.W.P.; writing—review and editing, A.F.d.l.T., G.S.-H. and E.V.-V.; supervision, M.W.P. and A.R.d.A.; funding acquisition, M.W.P., E.V.-V. and A.R.d.A. All authors have read and agreed to the published version of the manuscript.

Funding

M.W.P. acknowledges financial support from FONDECYT projects 1161092 and 1240129. A.F.d.l.T. is grateful for the support from FONDECYT project 11200057. C.V., M.R., C.C., and A.R.d.A. acknowledge support from PRONII-CONACYT (National Research Incentive Program of the National Council for Science and Technology) in Paraguay. This work was partially supported by the research project “Education, Investigation, and Biotechnology applied to Health”, FOCEM/MERCOSUR/COF/Number 03/11.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data are contained within the article or Supplementary Materials.

Acknowledgments

The authors thank the Agencia Nacional de Investigación y Desarrollo (ANID) and National Research Incentive Program of the National Council for Science and Technology.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Conteh, L.; Engels, T.; Molyneux, D.H. Socioeconomic aspects of neglected tropical diseases. Lancet 2010, 375, 239–247. [Google Scholar] [CrossRef] [PubMed]
  2. Pan American Health Organization. Health in the Americas 2007. In Regional, Scientific and Technical Publication 622; Pan American Health Organization: Washington, DC, USA, 2007. [Google Scholar]
  3. World Health Organization. First WHO Report on Neglected Tropical Diseases. In Working to Overcome the Global Impact Neglected Tropical Diseases; World Health Organization: Geneva, Switzerland, 2010; ISBN 978-92-4-1564090. [Google Scholar]
  4. Yamagata, Y.; Nakagawa, J. Control of Chagas disease. Adv. Parasitol. 2006, 61, 129–165. [Google Scholar]
  5. World Health Organization. Global Health Estimates 2014 Summary Tables: DALY by Cause, Age and Sex, by WHO Region, 2000–2012; World Health Organization: Geneva, Switzerland, 2014; Available online: http://www.who.int/news-room/facts-in-pictures/detail/chagas-disease (accessed on 10 October 2024).
  6. Meymandi, S.K.; Forsyth, C.J.; Soverow, J.; Hernandez, S.; Sanchez, D.; Montgomery, S.P.; Traina, M. Prevalence of Chagas disease in the Latin American-born population of Los Angeles. Clin. Infect. Dis. 2017, 64, 1182–1188. [Google Scholar] [CrossRef] [PubMed]
  7. Thompson, A.M.; O’Connor, P.D.; Yardley, V.; Maes, L.; Launay, D.; Braillard, S.; Chatelain, E.; Wan, B.; Franzblau, S.G.; Ma, Z.; et al. Novel linker variants of Antileishmanial/Antitubercular 7-substituted 2-nitroimidazooxazines offer enhanced solubility. ACS Med. Chem. Lett. 2021, 12, 275–281. [Google Scholar] [CrossRef]
  8. Roldos, V.; Nakayama, H.; Rolo, M.; Trucco, F.; Torres, S.; Vega, C.; Marrero-Ponce, Y.; Heguaburu, V.; Yaluff, G.; Go, A.; et al. Activity of a hydroxybibenzyl bryophyte constituent against Leishmania spp. and Trypanosoma cruzi: In silico, in vitro and in vivo activity studies. Eur. J. Med. Chem. 2008, 43, 1797–1807. [Google Scholar] [CrossRef]
  9. Vega, C.; Rolón, M.; Martínez-Fernández, A.R.; Escario, J.A.; Gómez-Barrio, A. A new pharmacological screening assay with Trypanosoma cruzi epimastigotes expressing beta-galactosidase. Parasitol. Res. 2005, 95, 296–298. [Google Scholar] [CrossRef]
  10. Santos, S.S.; de Araújo, R.V.; Giarolla, J.; Seoud, O.E.; Ferreira, E.I. Searching for drugs for Chagas disease, leishmaniasis and schistosomiasis: A review. Int. J. Antimicrob. Agents 2020, 55, 105906. [Google Scholar] [CrossRef]
  11. Lepesheva, G.I. Design or screening of drugs for the treatment of Chagas disease: What shows the most promise? Expert Opin. Drug Discov. 2013, 8, 1479–1489. [Google Scholar] [CrossRef] [PubMed]
  12. Scarim, C.B.; Jornada, D.H.; Chelucci, R.C.; de Almeida, L.; Dos Santos, J.L.; Chung, M.C. Current advances in drug discovery for Chagas disease. Eur. J. Med. Chem. 2018, 155, 824–838. [Google Scholar] [CrossRef]
  13. Lamim, M.; Domeneghini, L.; Rosaria, L.; Dias, S.; Kramer, L.; Regina, T.; Mascarello, A.; Steindel, M.; Augusto, R.; Carla, H.; et al. Trimethoxy-chalcone derivatives inhibit growth of Leishmania braziliensis: Synthesis, biological evaluation, molecular modeling and structure-activity relationship (SAR). Bioorg. Med. Chem. 2011, 19, 5046–5052. [Google Scholar]
  14. WHO. Research and Development to Meet Health Needs in Developing Countries; Report of the Consultative Expert Working Group on Research and Development: Strengthening Global Financing and Coordination; Financing and Coordination; World Health Organization: Geneva, Switzerland, 2012. [Google Scholar]
  15. Ortiz-Brizuela, E.; Menzies, D.; Behr, M.A. Testing and Treating Mycobacterium tuberculosis Infection. Med. Clin. N. Am. 2022, 106, 929–947. [Google Scholar] [CrossRef] [PubMed]
  16. Iskandar, K.; Murugaiyan, J.; Hammoudi Halat, D.; Hage, S.E.; Chibabhai, V.; Adukkadukkam, S.; Roques, C.; Molinier, L.; Salameh, P.; Van Dongen, M. Antibiotic discovery and resistance: The chase and the race. Antibiotics 2022, 11, 182. [Google Scholar] [CrossRef] [PubMed]
  17. World Health Organization. 2019. Available online: https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf?ua=1 (accessed on 10 October 2024).
  18. Johansen, M.D.; Herrmann, J.L.; Kremer, L. Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus. Nat. Rev. Microbiol. 2020, 18, 392–407. [Google Scholar] [CrossRef] [PubMed]
  19. Hooker, S.C. The constitution of lapachol and its derivatives. Part V. The structure of paternd’s “Isolapachone”. J. Am. Chem. Soc. 1936, 58, 1190–1197. [Google Scholar] [CrossRef]
  20. de la Torre, A.F.; Ali, A.; Westermann, B.; Schmeda-Hirschmann, G.; Pertino, M.W. An efficient cyclization of lapachol to new benzo[h]chromene hybrid compounds: A stepwise vs. one-pot esterification-click (CuAAC) study. New J. Chem. 2018, 42, 19591–19599. [Google Scholar] [CrossRef]
  21. Da Silva, E.N.; Menna-Barreto, R.F.S.; Pinto, M.d.C.F.R.; Silva, R.S.F.; Teixeira, D.V.; de Souza, M.C.B.V.; de Simone, C.A.; de Castro, S.L.; Ferreira, V.F.; Pinto, A.V. Naphthoquinoidal [1,2,3]-triazole, a new structural moiety active against Trypanosoma cruzi. Eur. J. Med. Chem. 2008, 43, 1774–1780. [Google Scholar] [CrossRef]
  22. Da Silva, E.N., Jr.; de Melo, I.M.M.; Diogo, E.B.T.; Costa, V.A.; Filho, J.D.S.; Valença, W.O.; Camara, C.A.; de Oliveira, R.N.; de Araujo, A.S.; Emery, F.S.; et al. On the search for potential anti-Trypanosoma cruzi drugs: Synthesis and biological evaluation of 2-hydroxy-3-methylamino and 1,2,3-triazolic naphthoquinoidal compounds obtained by click chemistry reactions. Eur. J. Med. Chem. 2012, 52, 304–312. [Google Scholar] [CrossRef]
  23. Da Silva, E.N., Jr.; Guimarães, T.T.; Menna-Barreto, R.F.S.; Pinto, M.C.F.R.; de Simone, C.A.; Pessoa, C.; Cavalcanti, B.C.; Sabino, J.R.; Andrade, C.K.Z.; Goulart, M.O.F.; et al. The evaluation of quinonoid compounds against Trypanosoma cruzi: Synthesis of imidazolic anthraquinones, nor-β-lapachone derivatives and β-lapachone-based 1,2,3-triazoles. Bioorg. Med. Chem. 2010, 18, 3224–3230. [Google Scholar] [CrossRef]
  24. Diogo, E.B.T.; Dias, G.G.; Rodrigues, B.L.; Guimarães, T.T.; Valença, W.O.; Camara, C.A.; de Oliveira, R.N.; da Silva, M.G.; Ferreira, V.F.; Paiva, Y.G.; et al. Synthesis and anti-Trypanosoma cruzi activity of naphthoquinone-containing triazoles: Electrochemical studies on the effects of the quinoidal moiety. Bioorg. Med. Chem. 2013, 21, 6337–6348. [Google Scholar] [CrossRef]
  25. Guimarães, T.T.; do Carmo, M.; Pinto, F.R.; Lanza, J.S.; Melo, M.N.; Monte-Neto, R.L.; de Melo, I.M.M.; Diogo, E.B.T.; Ferreira, V.F.; Camara, C.A.; et al. Potent naphthoquinones against antimony-sensitive and -resistant Leishmania parasites: Synthesis of novel α- and nor-α-lapachone based 1,2,3-triazoles by copper-catalyzed azide-alkyne cycloaddition. Eur. J. Med. Chem. 2013, 63, 523–530. [Google Scholar] [CrossRef]
  26. Pertino, M.W.; de la Torre, A.F.; Schmeda-Hirschmann, G.; Vega, C.; Rolon, M.; Coronel, C.; Rojas de Arias, A.; Leal Lopez, K.; Carranza-Rosales, P.; Viveros Valdez, E. Synthesis, trypanocidal and anti-leishmania activity of new triazole-lapachol and nor-lapachol hybrids. Bioorg. Chem. 2020, 103, 104122. [Google Scholar] [CrossRef] [PubMed]
  27. Van Bockstal, L.; Sádlová, J.; Suau, H.A.; Hendrickx, S.; Meneses, C.; Kamhawi, S.; Volf, P.; Maes, L.; Caljon, G. Impaired development of a miltefosine-resistant Leishmania infantum strain in the sand fly vectors Phlebotomus perniciosus and Lutzomyia longipalpis. IJP Drugs Drug Resist. 2019, 11, 1–7. [Google Scholar] [CrossRef] [PubMed]
  28. Rijal, S.; Ostyn, B.; Uranw, S.; Rai, K.; Bhattarai, N.R.; Dorlo, T.P.; Beijnen, J.H.; Vanaerschot, M.; Decuypere, S.; Dhakal, S.S.; et al. Increasing failure of miltefosine in the treatment of Kalaazar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clin. Infect. Dis. 2013, 56, 1530–1538. [Google Scholar] [CrossRef] [PubMed]
  29. Dhameliya, T.M.; Vekariya, D.D.; Patel, H.Y.; Patel, J.T. Comprehensive coverage on anti-mycobacterial endeavour reported during 2022. Eur. J. Med. Chem. 2023, 5, 255. [Google Scholar] [CrossRef]
  30. Copp, B.R. Antimycobacterial natural products. Nat. Prod. Rep. 2003, 20, 535–557. [Google Scholar] [CrossRef]
  31. Oliveira, R.A.; Azevedo-Ximenes, E.; Luzzati, R.; Garcia, R.C. The hydroxy-naphthoquinone lapachol arrests mycobacterial growth and immunomodulates host macrophages. Int. Immunopharmacol. 2010, 10, 1463–1473. [Google Scholar] [CrossRef]
  32. Ieque, A.L.; Carvalho, H.C.; Baldin, V.P.; Santos, N.C.S.; Costacurta, G.F.; Sampiron, E.G.; Fernandez de Andrade, C.M.M.; Siqueira, V.L.D.; Ferracioli, K.R.C.; Cardoso, R.F.; et al. Antituberculosis activities of lapachol and β-lapachone in combination with other drugs in acidic pH. Microb. Drug Resist. 2021, 27, 924–932. [Google Scholar] [CrossRef] [PubMed]
  33. Larsen, E.M.; Johnson, R.J. Microbial esterases and ester prodrugs: An unlikely marriage for combating antibiotic resistance. Drug Dev. Res. 2019, 80, 33–47. [Google Scholar] [CrossRef]
  34. Coll, P. Fármacos con actividad frente a Mycobacterium tuberculosis [Active drugs against Mycobacterium tuberculosis]. Enferm. Infecc. Microbiol. Clin. 2009, 27, 474–480. [Google Scholar] [CrossRef]
  35. Wu, M.L.; Aziz, D.B.; Dartois, V.; Dick, T. NTM drug discovery: Status, gaps and the way forward. Drug Discov. Today 2018, 23, 1502–1519. [Google Scholar] [CrossRef]
  36. Akram, S.M.; Attia, F.N. Mycobacterium avium Complex. In StatPearls [Internet]; StatPearls Publishing: Treasure Island, FL, USA, 2023. Available online: https://www.ncbi.nlm.nih.gov/books/NBK431110/# (accessed on 10 October 2024).
  37. Lin, S.; Hua, W.; Wang, S.; Zhang, Y.; Chen, X.; Liu, H.; Shao, L.; Chen, J.; Zhang, W. In vitro assessment of 17 antimicrobial agents against clinical Mycobacterium avium complex isolates. BMC Microbiol. 2022, 22, 175. [Google Scholar] [CrossRef] [PubMed]
  38. Cohen, R.; Dortet, L.; Caseris, M.; Raymond, J.; Lorrot, M.; Toubiana, J. Treatment of Resistant Gram-negative bacilli in children. Infect. Dis. Now 2023, 53, 104794. [Google Scholar] [CrossRef] [PubMed]
  39. Zhou, G.; Wang, Q.; Wang, Y.; Wen, X.; Peng, H.; Peng, R.; Shi, Q.; Xie, X.; Li, L. Outer Membrane Porins Contribute to Antimicrobial Resistance in Gram-Negative Bacteria. Microorganisms 2023, 11, 1690. [Google Scholar] [CrossRef] [PubMed]
  40. Sangwan, J.; Kaushik, C.P.; Kumar, L.; Sindhu, J.; Chahal, M. Design, synthesis and antimicrobial activities of 1,2,3-triazole hybrids with amine-ester functionality. Med. Chem. Res. 2024, 33, 77–88. [Google Scholar] [CrossRef]
  41. Lipinski, C.A.; Iombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 1997, 23, 3–25. [Google Scholar] [CrossRef]
  42. Waring, M.J.; Arrowsmith, J.; Leach, A.R.; Leeson, P.D.; Mandrell, S.; Owen, R.M. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat. Rev. Drug Discov. 2015, 14, 475–486. [Google Scholar] [CrossRef]
  43. Meanwell, N.A. Improving drug candidates by design: A focus on physicochemical properties as a means of improving compound disposition and safety. Chem. Res. Toxicol. 2011, 24, 1420–1456. [Google Scholar] [CrossRef]
  44. Ertl, P.; Rohde, B.; Selzer, P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J. Med. Chem. 2000, 43, 3714–3717. [Google Scholar] [CrossRef]
  45. Daina, A.; Michielin, O.; Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017, 7, 42717. [Google Scholar] [CrossRef] [PubMed]
  46. Potts, R.O.; Guy, R.H. Predicting skin permeability. Pharm. Res. 1992, 9, 663–669. [Google Scholar] [CrossRef]
  47. Mikus, J.; Steverding, D. A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue. Parasitol. Int. 2000, 48, 265–269. [Google Scholar] [CrossRef] [PubMed]
  48. Rolón, M.; Seco, E.M.; Vega, C.; Nogal, J.J.; Escario, A.; Gómez-Barrio, A.; Malpartida, F. Selective activity of polyene macrolides produced by genetically modified Streptomyces on Trypanosoma cruzi. Int. J. Antimicrob. Agents 2006, 28, 104–109. [Google Scholar] [CrossRef] [PubMed]
  49. Telenti, A.; Marchesi, F.; Balz, M.; Bally, F.; Böttger, E.C.; Bodmer, T. Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis. J. Clin. Microbiol. 1993, 31, 175–178. [Google Scholar] [CrossRef] [PubMed]
Pharmaceuticals 17 01375 g001
Figure 1. Structural diversity of antiprotozoal lapachol derivatives [21,22,23,24,25,26].
Figure 1. Structural diversity of antiprotozoal lapachol derivatives [21,22,23,24,25,26].
Pharmaceuticals 17 01375 g001
Pharmaceuticals 17 01375 sch001
Scheme 1. Derivatives of benzo[h]chromene.
Scheme 1. Derivatives of benzo[h]chromene.
Pharmaceuticals 17 01375 sch001
Table 1. Antiprotozoal activity of the lapachol–triazole derivatives on Leishmania brazilensis (L. b) and Leishmania infantum (L. i) promastigotes, and T. cruzi epimastigotes and cytotoxicity on NCTC929 fibroblast cells.
Table 1. Antiprotozoal activity of the lapachol–triazole derivatives on Leishmania brazilensis (L. b) and Leishmania infantum (L. i) promastigotes, and T. cruzi epimastigotes and cytotoxicity on NCTC929 fibroblast cells.
CompoundLeishmanicidal
Activity (µM)		Trypanocidal Activity (µM)Cytotoxicity (µM)Selectivity Index *
IC50—L. bIC50—L. iIC50 T. cruziCC50—L929L929/
L. b		L929/
L. i		L929/
T. cruzi
1a10.724.919.2106.41046
1b6.730.537.31281943
2a>256>25668.7>256NENE>4
3a>256>256>256>256NENENE
2b>256>256204.3>256NENE>1
3b>256>256>256>256NENENE
2c>256>256>256>256NENENE
3c>256>256>256>256NENENE
2d>256>256>256>256NENENE
3d>256>256>256>256NENENE
2e>256>256>256>256NENENE
3e>256>256>256>256NENENE
2f14.538.221.131.8212
3f17.646.624.7312.218713
2g>256>256>256>384>2>2>2
3g>256>256146.5>384>2>2>3
2h>256>256>256>256NENENE
3h>256>256>256>256NENENE
2i>256>256>256>256NENENE
3i>256>256>256>256NENENE
Miltefosine64.025.1NA275443.0109.7NA
BenznidazoleNANA54.7769NANA14.0
* SI = (CC50 L929/IC50 parasites); NA: not applicable; NE: not estimable; IC50 and CC50 values > 256 µM.
Table 2. MIC values (µg/mL) of samples against mycobacteria clinical strains. Only compounds active at <200 μg/mL in some mycobacterial strains are presented.
Table 2. MIC values (µg/mL) of samples against mycobacteria clinical strains. Only compounds active at <200 μg/mL in some mycobacterial strains are presented.
Strain1a3e2f3f3h* Rifampicin* Linezolid* Imipenem
M. tuberculosis CIPTIR -D152>200>200>200>200>20032NANA
M. tuberculosis CIPTIR-F296>200>200>200>200>2001NANA
M. tuberculosis ATCC H37Rv>200>200>200>200>2002NANA
M. abscessus LIID-01>200>200>200100100NA132
M. abscessus LIID-02>200>200>200100100NA132
M. abscessus LIID-03>200>200>200100100NA18
M. fortuitum LIID-01>200>200>200100>200NA84
M. intracellulare LIID-01505050100>200NA21
M. intracellulare LIID-02>200>200>200>200>200NA8>64
* Reference drug, NA: not applicable.
Table 3. MIC values (µg/mL) of samples against selected clinical strains of bacteria. Only compounds active at <200 μg/mL in some mycobacterial strains are presented.
Table 3. MIC values (µg/mL) of samples against selected clinical strains of bacteria. Only compounds active at <200 μg/mL in some mycobacterial strains are presented.
Strain1a3e2f3f3h* Gentamicin
E. coli (G−)>200>200>200100>2000.2
P. aeruginosa (G−)>200>200>200100>2000.78
S. typhi (G−)>200100>200>2001000.1
S. aureus (G+)100>200>2001001000.1
L. innocua (G+)>200>200>200100>2001.56
L. monocytogenes (G+)>200>200>200100>2000.2
E. faecalis (G+)>200>200>200>200>2000.78
B. cereus (G+)>200>200>200100>2000.78
M. luteus (G+)>200>200>200100>2000.78
* Reference drug.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Pertino, M.W.; F. de la Torre, A.; Schmeda-Hirschmann, G.; Vega Gómez, C.; Rolón, M.; Coronel, C.; Rojas de Arias, A.; Molina-Torres, C.A.; Vera-Cabrera, L.; Viveros-Valdez, E. Exploring Benzo[h]chromene Derivatives as Agents against Protozoal and Mycobacterial Infections. Pharmaceuticals 2024, 17, 1375. https://doi.org/10.3390/ph17101375

AMA Style

Pertino MW, F. de la Torre A, Schmeda-Hirschmann G, Vega Gómez C, Rolón M, Coronel C, Rojas de Arias A, Molina-Torres CA, Vera-Cabrera L, Viveros-Valdez E. Exploring Benzo[h]chromene Derivatives as Agents against Protozoal and Mycobacterial Infections. Pharmaceuticals. 2024; 17(10):1375. https://doi.org/10.3390/ph17101375

Chicago/Turabian Style

Pertino, Mariano Walter, Alexander F. de la Torre, Guillermo Schmeda-Hirschmann, Celeste Vega Gómez, Miriam Rolón, Cathia Coronel, Antonieta Rojas de Arias, Carmen A. Molina-Torres, Lucio Vera-Cabrera, and Ezequiel Viveros-Valdez. 2024. "Exploring Benzo[h]chromene Derivatives as Agents against Protozoal and Mycobacterial Infections" Pharmaceuticals 17, no. 10: 1375. https://doi.org/10.3390/ph17101375

APA Style

Pertino, M. W., F. de la Torre, A., Schmeda-Hirschmann, G., Vega Gómez, C., Rolón, M., Coronel, C., Rojas de Arias, A., Molina-Torres, C. A., Vera-Cabrera, L., & Viveros-Valdez, E. (2024). Exploring Benzo[h]chromene Derivatives as Agents against Protozoal and Mycobacterial Infections. Pharmaceuticals, 17(10), 1375. https://doi.org/10.3390/ph17101375

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop